MA
PDLI

MYDA Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

MYDA Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-125,000
Closed -$406K – 197
2019
Q4 		$406K Buy
+125,000
New +$363K 0.18% 77

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ECM
Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MYDA Advisors's PDLI Position: Q1 2020 in Review

MYDA Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q1 2020, closing a stake of 125,000 shares — an estimated $406K sold.

MYDA Advisors first reported a position in PDLI in Q4 2019 and held it in 1 quarter. The position peaked at $406K in Q4 2019. 133 funds tracked by Wall St. Rank hold PDLI as of Q1 2020.

  • MYDA Advisors reported no remaining PDL BioPharma, Inc. position as of Q1 2020 after selling out during the quarter.
  • MYDA Advisors sold 125,000 PDL BioPharma, Inc. shares in Q1 2020, an estimated $406K.
  • MYDA Advisors first reported a position in PDL BioPharma, Inc. in Q4 2019 and held it in 1 quarter.
  • MYDA Advisors's PDL BioPharma, Inc. position peaked at $406K in Q4 2019.
  • 133 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2020.

Based on MYDA Advisors's 13F filing for Q1 2020, filed 14 May 2020.